Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | ARG1 | P05089 | 2/20 | 0.35 |
| ▸ | ARG2 | P78540 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656348 | 1.00 | SPHK2 (0.46) | SPHK2SPHK1POLBL3MBTL1PARP1 | |
| SCHEMBL8136699 | 1.00 | SPHK2 (0.46) | SPHK2SPHK1POLBL3MBTL1PARP1 | |
| SCHEMBL13683452 | 0.95 | SPHK2 (0.41) | SPHK2SPHK1POLBL3MBTL1PARP1 | |
| SCHEMBL12391783 | 0.84 | SPHK2 (0.43) | SPHK2SPHK1HRH3S1PR1S1PR3 | |
| SCHEMBL8136742 | 0.83 | ATM (0.36) | SPHK2SPHK1HRH3ARG1ARG2 | |
| SCHEMBL13683454 | 0.81 | HTT (0.41) | SPHK2SPHK1ARG1ARG2S1PR1 | |
| SCHEMBL12156688 | 0.81 | POLB (0.42) | SPHK2SPHK1POLBL3MBTL1PARP1 | |
| SCHEMBL12891024 | 0.81 | POLB (0.42) | SPHK2SPHK1POLBL3MBTL1PARP1 | |
| SCHEMBL12891026 | 0.81 | POLB (0.42) | SPHK2SPHK1POLBL3MBTL1PARP1 | |
| SCHEMBL13965733 | 0.80 | OPRD1 (0.50) | HRH3ARG1ARG2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | SPHK2 3409/4885SPHK1 3303/4885POLB 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.